Search

COVID-19 pandemic is recognized as a present day major public health burden. Risk factors for developing a more severe course of COVID-19 include increased levels of C-reactive protein and D-dimer. Pulmonary embolism (PE) is challenging in patients with COVID-19. The purpose: to analyze clinical and paraclinical manifestations of PE in patients with COVID-19 in order to develop a system for its early diagnosis, prediction of complications, prevention and treatment. 52 patients aged 28 - 81 y.o. with a diagnosis "Acute respiratory disease COVID-19" have been examined during 2020-2021. (98.08±1.9)% of PE patients had a history of one or more comorbidities, including obesity (80.77%), coronary heart disease (96.15%), hypertension (98.08%), peripheral arteries (92.3%), type 2 diabetes mellitus (48.08%). Evaluation of laboratory parameters revealed increasing lymphocytopenia, leukocytosis, neutrophilia, thrombocytopenia (p

The work involved a molecular biological technique (ISSR-PCR) using ISSR-primer S-2, with structure (AGC) 6G. Changes in the gastric mucosa in chronic duodenal ulcer disease against the background of severe chronic atrophic gastritis have been analyzed. Noteworthy is the fact that there is a strong correlation between the degree of dysplasia of the epithelium of the gastric mucosa and the mitotic index, the Pearson's correlation coefficient rxy was 0.853, respectively. A strong and very strong correlation relationship between the indicators of the degree of dysplasia of the epithelium of the gastric mucosa by phenotypic characteristics and indicators of DNA typing of samples of the gastric mucosa, the Pearson's correlation coefficient rxy was 0.863, respectively. DNA profiles of the gastric mucosa of patients with duodenal ulcer according to the results of typing by the ISSR-PCR method ranging from 520 to 620 bp. had the character of microsatellite expansions and differed from the profile of the norm, which is evidence of precancerous changes.

Este artículo discute la actividad estructural y dinámica de los sistemas financieros del mundo durante la crisis de 2008 y hace una propuesta sobre cómo predecir las crisis financieras.

Aim: This research is dedicated to development of a methodology for the determination of gliclazide in biological samples for analytical diagnostics of lethal overdose caused by the drug. Materials and Methods: TLC method: chromatographic plates Merck silica gel 60 F254 10×10 cm in size, mobile phase - ethyl acetate, visualization reagent 1% vanillin solution or 5% solution of chloral hydrate. HPLC method: liquid chromatograph «Milichrom-A-02» with UV detecting (RF); Prontosil-120-5-C18-AQ reverse-phase column Ø2×75 mm in diameter, 5 μm grains (Bischoff Analysetechnik und Geräte GmbH, Germany); Gradient elution with a mixture of two eluents (eluent A – [0.2 M solution LiClO4 – 0.005 M solution of HClO4] and eluent B - acetonitrile); Wavelength 230 nm. Results: Methodology for the determination of gliclazide in biological samples is developed. It includes an effective method of gliclazide isolation from the objects of the study, specific and selective chromatographic detection methods and quantitative determination of toxicity in the extracts that had been received. It was established that while using TLC method gliclazide was assigned an Rf value of 0,48±0,01; detection limit is 3.0 μg. When applying HPLC method gliclazide holding time was 7.80 min (RSD = 0.13%), detection limit was 0.050 μg / ml, limit of the quantitative determination was 0.157 μg/ml, linearity of the procedure was in the range of 0.1-20.0 μg/ml. Under the developed conditions, gliclazide was determined at 17.48 ± 1.32 μg/ml (RSD = 6.06%). Conclusions: Results of the study indicate that methodology for the determination of gliclazide in biological samples that was developed can be used for analytical diagnostics of lethal overdose caused by the drug.